CU24705B1 - Antígeno quimérico que comprende el dominio extracelular de pd-l1 - Google Patents

Antígeno quimérico que comprende el dominio extracelular de pd-l1

Info

Publication number
CU24705B1
CU24705B1 CU2020000075A CU20200075A CU24705B1 CU 24705 B1 CU24705 B1 CU 24705B1 CU 2020000075 A CU2020000075 A CU 2020000075A CU 20200075 A CU20200075 A CU 20200075A CU 24705 B1 CU24705 B1 CU 24705B1
Authority
CU
Cuba
Prior art keywords
chimeric antigen
extracellular domain
multimer
ligand
pharmaceutically acceptable
Prior art date
Application number
CU2020000075A
Other languages
English (en)
Other versions
CU20200075A7 (es
Inventor
Ávila Marta Ayala
Romero Mónica Bequet
Pérez Vladimir Armando Besada
Ayala Camila Canaán-Haden
Rodríguez Luis Ariel Espinosa
COWLEY Jorge Víctor GAVILONDO
Blanco Sonia Gonzalez
Moya Isabel Gonzalez
Fernández Miladys Limonta
DÍAZ Yanelys MORERA
Ramírez Javier Sánchez
Original Assignee
Ct Ingenieria Genetica Biotecnologia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotecnologia filed Critical Ct Ingenieria Genetica Biotecnologia
Priority to CU2020000075A priority Critical patent/CU24705B1/es
Priority to AU2021363436A priority patent/AU2021363436A1/en
Priority to CN202180072039.2A priority patent/CN116783221A/zh
Priority to US18/033,035 priority patent/US20230390369A1/en
Priority to JP2023524660A priority patent/JP7585480B2/ja
Priority to KR1020237015994A priority patent/KR20230107810A/ko
Priority to CA3196460A priority patent/CA3196460A1/en
Priority to MX2023004718A priority patent/MX2023004718A/es
Priority to PCT/CU2021/050008 priority patent/WO2022083805A1/es
Priority to EP21806135.6A priority patent/EP4234029A1/en
Publication of CU20200075A7 publication Critical patent/CU20200075A7/es
Publication of CU24705B1 publication Critical patent/CU24705B1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

<p>Antígeno quimérico que comprende el dominio extracelular del ligando 1 del receptor proteico de muerte celular programada 1 (PD-L1) humano y que forma un multímero que tiene reducida la capacidad de unión a los receptores PD-1 y CD80 respecto a la forma nativa de PD-L1. La composición farmacéutica que comprende dicho antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable.</p>
CU2020000075A 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1 CU24705B1 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1
AU2021363436A AU2021363436A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
CN202180072039.2A CN116783221A (zh) 2020-10-22 2021-09-28 包含pd-l1的胞外结构域的嵌合抗原
US18/033,035 US20230390369A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
JP2023524660A JP7585480B2 (ja) 2020-10-22 2021-09-28 Ｐｄ－ｌ１の細胞外ドメインを含むキメラ抗原
KR1020237015994A KR20230107810A (ko) 2020-10-22 2021-09-28 Pd-l1의 세포 외 도메인을 포함하는 키메라 항원
CA3196460A CA3196460A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1
MX2023004718A MX2023004718A (es) 2020-10-22 2021-09-28 Antigeno quimerico que comprende el dominio extracelular de pd-l1.
PCT/CU2021/050008 WO2022083805A1 (es) 2020-10-22 2021-09-28 Antígeno quimérico que comprende el dominio extracelular de pd-l1
EP21806135.6A EP4234029A1 (en) 2020-10-22 2021-09-28 Chimeric antigen comprising the extracellular domain of pd-l1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Publications (2)

Publication Number Publication Date
CU20200075A7 CU20200075A7 (es) 2022-05-11
CU24705B1 true CU24705B1 (es) 2024-06-11

Family

ID=78598633

Family Applications (1)

Application Number Title Priority Date Filing Date
CU2020000075A CU24705B1 (es) 2020-10-22 2020-10-22 Antígeno quimérico que comprende el dominio extracelular de pd-l1

Country Status (10)

Country Link
US (1) US20230390369A1 (es)
EP (1) EP4234029A1 (es)
JP (1) JP7585480B2 (es)
KR (1) KR20230107810A (es)
CN (1) CN116783221A (es)
AU (1) AU2021363436A1 (es)
CA (1) CA3196460A1 (es)
CU (1) CU24705B1 (es)
MX (1) MX2023004718A (es)
WO (1) WO2022083805A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025189420A1 (en) * 2024-03-14 2025-09-18 Topmunnity Therapeutics Taiwan Limited Chimeric antigen receptor against programmed deathligand 1 (pd-l1) and application thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6149921A (en) 1993-12-29 2000-11-21 Centro De Inmunologia Molecular Vaccine compositions for eliciting an immune response against N-acetylated gangliosides and their use for cancer treatment
CU22559A1 (es) 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
BR112014009526B8 (pt) * 2011-10-17 2023-01-17 Herlev Hospital Composição de vacina compreendendo pd-l1, kit de partes compreendendo tal composição e uso dos mesmos para tratar ou prevenir câncer
CN105705522B (zh) * 2013-05-14 2020-09-15 上海亨臻实业有限公司 针对低免疫原性蛋白的表位疫苗及其制法和用途
CN109689096A (zh) * 2016-05-18 2019-04-26 阿尔伯特爱因斯坦医学院公司 变体pd-l1多肽、t细胞调节性多聚体多肽及其使用方法
KR20190125481A (ko) 2017-03-17 2019-11-06 백심 아게 암의 면역요법을 위한 신규 pd-l1 표적화 dna 백신
CU24534B1 (es) 2017-11-06 2021-07-02 Ct Inmunologia Molecular Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3

Also Published As

Publication number Publication date
US20230390369A1 (en) 2023-12-07
AU2021363436A9 (en) 2024-10-10
JP2023546485A (ja) 2023-11-02
CA3196460A1 (en) 2022-04-28
WO2022083805A1 (es) 2022-04-28
JP7585480B2 (ja) 2024-11-18
CN116783221A (zh) 2023-09-19
MX2023004718A (es) 2023-05-10
CU20200075A7 (es) 2022-05-11
KR20230107810A (ko) 2023-07-18
AU2021363436A1 (en) 2023-06-01
EP4234029A1 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
CL2019002250A1 (es) Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco. (divisional solicitud 201803520)
MX2020013443A (es) Receptores de antigeno quimerico de bcma y usos de los mismos.
MX2016015383A (es) Receptores de celulas t anti - papilomavirus 16 e7 humano.
MX2021005022A (es) Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
MX2017006865A (es) Receptores de células t de kras anti-mutado.
CL2021001706A1 (es) Receptores de antígenos quiméricos dirigidos a bcma y métodos de uso de estos (divisional de solicitud no. 201900326)
PE20190115A1 (es) Anticuerpos vista antihumanos y su uso
IL285182A (en) Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ror1)
AR118560A2 (es) Métodos y composiciones que comprenden polipéptidos recombinantes purificados
CL2019003143A1 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso.
CO2021007691A2 (es) Anticuerpos monoclonales antagonistas contra cd40 y sus usos
MA51993A (fr) Anticorps anti-cd25 pour la déplétion de cellules spécifiques d&#39;une tumeur
CR20200170A (es) Receptores de células t que reconocen p53 mutado
MX2022015399A (es) Conjugados de superficie celular y composiciones y metodos celulares relacionados.
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
MX2018003062A (es) Receptores de celula t que reconocen kras mutante restringido en hla-cw8.
PE20241349A1 (es) Anticuerpos de union a cd3
AR112902A1 (es) Receptores de células t restringidas a hla de clase ii contra ras mutado
PE20220220A1 (es) Anticuerpos y fragmentos de anticuerpo para la conjugacion sitio-especifica
AR093788A1 (es) Inmunoterapia con agentes de enlace
MX2020001358A (es) Celulas t que redirigen el receptor del antigeno quimerico especifico cd123 y metodos de su uso.
MX2018012539A (es) Composiciones y métodos de células t receptoras de aloantígeno quimérico.
MX2015003061A (es) Receptores de la celula t que reconocen mhc de mage-a3 de calse ii-restringida.
MX2019013923A (es) Receptores de antigenos quimericos que se dirigen a flt3.
MX2016008076A (es) Receptores quimericos de antigeno de mesotelina humana y uso de los mismos.